MDS-O 200mg Tablet
Marketer
Adley Formulations
Salt Composition
Azacitidine (200mg)
Overview MDS-O 200mg Tablet
Azacitidine 200mg tablets are indicated in the management of certain hematological malignancies. This medication treats adult patients across all Myelodysplastic Syndrome (MDS) subtypes. Other uses may be determined by your physician. Azacitidine 200mg tablets can be administered with or without food, but consistent daily timing is recommended. Dosage and frequency are determined by your doctor based on your specific condition and may be adjusted. Adhere strictly to your prescribed regimen; improper use or overdose can lead to severe adverse reactions. Therapeutic effects may take weeks or months to manifest; discontinue only under medical guidance. Common side effects include emesis, fatigue, nausea, and pyrexia. Report any concerning symptoms to your doctor; management strategies may be available. Vaccination should be discussed with your doctor before administration. Regular blood work, including cardiac, hepatic, and renal function assessments, is necessary. Prior to commencement, inform your doctor of any pre-existing liver or kidney conditions, or concurrent use of antimicrobial agents. Significant drug interactions are possible; disclose all medications currently being taken. This medication is contraindicated during gestation and lactation.
Uses of MDS-O 200mg Tablet
Myelodysplastic syndrome therapies and blood cancer treatment
Major Benefits of MDS-O 200mg Tablet:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The MDS-O 200mg Tablet can be consumed with or without food, although consistent timing is recommended.
Common Side effects of MDS-O 200mg Tablet:
- Vomiting
- Weakness
- Nausea
- Decreased potassium level in blood
- Bruise
- Fever
- Chills
- Diarrhea
- Constipation
How to use MDS-O 200mg Tablet:
Consume this medication precisely as directed by your physician, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The MDS-O 200mg Tablet can be administered with or without food, although consistent timing is recommended.
How MDS-O 200mg Tablet works:
Leukemia patients may be prescribed the anticancer drug MDS-O 200mg Tablet. Its mechanism of action involves disrupting the DNA and RNA of cancerous cells, thereby inducing cell death and promoting the healthy development of new blood cells within the bone marrow.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside MDS-O 200mg Tablet may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Taking 200mg MDS-O tablets during pregnancy poses a confirmed risk to fetal development and is therefore inadvisable. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingUNSAFE
Breastfeeding mothers should avoid MDS-O 200mg tablets. Evidence indicates potential infant harm from this medication.
DrivingUNSAFE
Driving ability may be impaired by side effects, including fatigue, associated with MDS-O 200mg Tablets. The medication may induce drowsiness, potentially impacting driving capabilities.
KidneyCAUTION
Patients with kidney impairment should use the 200mg MDS-O tablet cautiously; dosage modification may be necessary. Physician consultation is advised.
LiverCAUTION
Individuals with hepatic impairment should use MDS-O 200mg tablets cautiously, potentially requiring dosage modification. Physician consultation is advised. MDS-O 200mg tablets are contraindicated in patients exhibiting advanced hepatocellular carcinoma.
What if you forget to take MDS-O 200mg Tablet :
NA
Facts to Know About MDS-O 200mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Pyrimidine Nucleoside Analog |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Action Category | Metabolic Inhibitors |
3,018 People bought this recently